BIAL and Neurocrine Announce Exclusive North American Licensing Agreement for Opicapone

ONGENTYS®(opicapone) Approved in Europe in June 2016Porto, Portugal and San Diego, California, February 10, 2017 - BIAL and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America. ONGENTYS® (opicapone) is a once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor (COMT inhibitor) that was approved in June 2016 by the European Commission as an adjunct therapy to preparations of levodopa/DOPA decarboxylase inhibitors for